What Is Retatrutide and Where Does It Sit in the GLP Class?

Retatrutide (LY3437943) is a single-molecule triple agonist that targets the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor simultaneously. That triple-receptor profile sets it apart from approved agents in the same class. Semaglutide, sold as Ozempic and Wegovy, is a GLP-1 single agonist with FDA approval for specific indications under those brand names. Tirzepatide, sold as Mounjaro and Zepbound, is a dual GIP/GLP-1 agonist also carrying FDA approval under those specific branded products. Retatrutide adds glucagon receptor activity on top of both, which researchers hypothesize may drive greater energy expenditure.

The glucagon component is the key differentiator under study. Glucagon receptor activation increases metabolic rate and promotes fat oxidation in animal models, though the clinical translation of that mechanism in humans is still being characterized through ongoing trials. Retatrutide is being developed by Eli Lilly and Company, the same manufacturer behind tirzepatide. The compound has no approved brand name, no prescription pathway, and no regulatory clearance in any market as of this writing.

Phase 2 Readout: The Numbers That Moved the Needle

The pivotal Phase 2 data for retatrutide in adults with obesity were published in The New England Journal of Medicine in July 2023. The randomized, double-blind, placebo-controlled trial enrolled 338 participants across multiple dose cohorts over 48 weeks. Participants in the highest-dose cohort (24 mg) achieved a mean body-weight reduction of approximately 24.2 percent from baseline at 48 weeks. That figure drew significant attention because it exceeded the 48-week weight-loss percentages reported in Phase 3 trials for both semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) in their respective pivotal studies.

The trial also included a cohort of participants with type 2 diabetes. In that subgroup, retatrutide produced mean HbA1c reductions of up to 2.02 percentage points from baseline at 24 weeks, alongside substantial weight loss. Adverse events were consistent with the GLP class generally: nausea, vomiting, and diarrhea were the most common, and they were more frequent at higher doses. These are Phase 2 findings from a single study with a few hundred participants. Phase 3 trials with thousands of participants are required before any regulatory submission can occur.

Current Phase 3 Status

Eli Lilly initiated the TRIUMPH Phase 3 program for retatrutide. As of mid-2025, multiple Phase 3 trials are listed as active or recruiting on ClinicalTrials.gov. The program covers obesity, type 2 diabetes, and cardiovascular outcomes. TRIUMPH-1 (NCT05929066) is evaluating retatrutide in adults with obesity or overweight with at least one weight-related comorbidity over a 72-week primary endpoint period. Enrollment targets for individual TRIUMPH trials run into the thousands of participants, which is standard for a registration-track obesity program.

A cardiovascular outcomes trial is also part of the Phase 3 package. Regulatory agencies including the FDA now expect cardiovascular outcomes data for weight-management drugs, following the precedent set by the SELECT trial for semaglutide. Lilly has not announced a projected NDA submission date publicly as of this update. Phase 3 programs of this scale typically require two to four years from first enrollment to data lock, placing any potential submission in the 2026-2027 window at the earliest, though that timeline is speculative and subject to change based on enrollment pace and interim analyses.

• TRIUMPH Phase 3 program: active as of mid-2025
• Primary indication under study: obesity and overweight with comorbidities
• Additional arms: type 2 diabetes, cardiovascular outcomes
• No NDA or BLA submission announced as of this writing

Regulatory Milestones: What Has and Has Not Happened

As of mid-2025, retatrutide has received no FDA approval, no European Medicines Agency (EMA) approval, and no equivalent regulatory clearance in any jurisdiction. There is no branded drug product. This is a critical distinction for readers comparing retatrutide to other compounds in the GLP class. Wegovy (semaglutide 2.4 mg) received FDA approval for chronic weight management in adults in June 2021. Zepbound (tirzepatide) received FDA approval for the same indication in November 2023. Those approvals apply specifically to those branded pharmaceutical products manufactured under FDA-regulated conditions, not to research-chemical versions of the same molecules.

Retatrutide has not reached the submission stage. The FDA's standard review pathway for a new molecular entity requires a completed Phase 3 package, safety data from thousands of patients, and manufacturing documentation before an NDA can be filed. Fast Track designation, if granted, accelerates review after submission but does not change the requirement for Phase 3 completion. Lilly has not publicly confirmed Fast Track status for retatrutide as of this update. Any research-chemical product labeled 'retatrutide' sold through online vendors is not FDA-approved and has not passed the safety and efficacy review process required for prescription drugs.

What Changed in 2024 and 2025

The most significant development in 2024 was the formal launch of the TRIUMPH Phase 3 program, with multiple trial registrations appearing on ClinicalTrials.gov across the second and third quarters of 2024. Lilly also presented additional Phase 2 subgroup analyses at major endocrinology conferences, including data on retatrutide's effects on liver fat content in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). Those analyses were exploratory and drawn from a small subset of the Phase 2 cohort, so they carry the weight of hypothesis-generating data rather than confirmatory evidence.

In early 2025, Lilly confirmed that retatrutide Phase 3 enrollment was ongoing across multiple sites globally. No interim efficacy readouts from Phase 3 have been made public as of this writing. The competitive context shifted in 2024 and 2025 as other triple agonists and next-generation GLP compounds entered earlier-phase trials from competing manufacturers, meaning retatrutide is no longer the only triple-receptor compound in human studies. Lilly's head start in Phase 3 enrollment remains a meaningful advantage in the race toward a potential regulatory submission.